vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and DORCHESTER MINERALS, L.P. (DMLP). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $41.9M, roughly 1.9× DORCHESTER MINERALS, L.P.). DORCHESTER MINERALS, L.P. runs the higher net margin — 38.7% vs -9.6%, a 48.3% gap on every dollar of revenue. On growth, DORCHESTER MINERALS, L.P. posted the faster year-over-year revenue change (5.4% vs -16.8%). Over the past eight quarters, DORCHESTER MINERALS, L.P.'s revenue compounded faster (16.2% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Dorchester Minerals, L.P. is a publicly traded master limited partnership based in the United States. It acquires, owns, and manages a diversified portfolio of royalty interests, net profit interests, and mineral properties associated with oil, natural gas, and natural gas liquids production across key onshore U.S. energy basins, delivering stable cash flow returns to its unitholders.

BIOX vs DMLP — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.9× larger
BIOX
$77.6M
$41.9M
DMLP
Growing faster (revenue YoY)
DMLP
DMLP
+22.2% gap
DMLP
5.4%
-16.8%
BIOX
Higher net margin
DMLP
DMLP
48.3% more per $
DMLP
38.7%
-9.6%
BIOX
Faster 2-yr revenue CAGR
DMLP
DMLP
Annualised
DMLP
16.2%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
DMLP
DMLP
Revenue
$77.6M
$41.9M
Net Profit
$-7.4M
$16.2M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
-9.6%
38.7%
Revenue YoY
-16.8%
5.4%
Net Profit YoY
-20.2%
13.7%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
DMLP
DMLP
Q4 25
$41.9M
Q3 25
$77.6M
$35.4M
Q2 25
$32.4M
Q1 25
$60.6M
$43.2M
Q4 24
$98.8M
$39.7M
Q3 24
$93.3M
$53.5M
Q2 24
$37.4M
Q1 24
$84.0M
$31.0M
Net Profit
BIOX
BIOX
DMLP
DMLP
Q4 25
$16.2M
Q3 25
$-7.4M
$11.2M
Q2 25
$12.3M
Q1 25
$-1.6M
$17.6M
Q4 24
$605.2K
$14.2M
Q3 24
$-6.2M
$36.4M
Q2 24
$23.6M
Q1 24
$9.8M
$18.2M
Gross Margin
BIOX
BIOX
DMLP
DMLP
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
DMLP
DMLP
Q4 25
Q3 25
9.3%
Q2 25
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q2 24
Q1 24
15.7%
Net Margin
BIOX
BIOX
DMLP
DMLP
Q4 25
38.7%
Q3 25
-9.6%
31.5%
Q2 25
38.1%
Q1 25
-2.6%
40.9%
Q4 24
0.6%
35.9%
Q3 24
-6.6%
68.1%
Q2 24
63.2%
Q1 24
11.6%
58.6%
EPS (diluted)
BIOX
BIOX
DMLP
DMLP
Q4 25
Q3 25
$-0.12
Q2 25
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.10
Q2 24
Q1 24
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
DMLP
DMLP
Cash + ST InvestmentsLiquidity on hand
$15.5M
$41.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
Total Assets
$734.9M
$309.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
DMLP
DMLP
Q4 25
$41.9M
Q3 25
$15.5M
$41.6M
Q2 25
$36.5M
Q1 25
$38.5M
$41.5M
Q4 24
$29.2M
$42.5M
Q3 24
$32.3M
$56.5M
Q2 24
$35.2M
Q1 24
$16.4M
$37.7M
Stockholders' Equity
BIOX
BIOX
DMLP
DMLP
Q4 25
Q3 25
$288.3M
Q2 25
Q1 25
$345.0M
Q4 24
$346.3M
Q3 24
$346.0M
Q2 24
Q1 24
$348.5M
Total Assets
BIOX
BIOX
DMLP
DMLP
Q4 25
$309.6M
Q3 25
$734.9M
$330.4M
Q2 25
$325.6M
Q1 25
$798.2M
$349.0M
Q4 24
$835.2M
$366.8M
Q3 24
$827.3M
$403.4M
Q2 24
$176.0M
Q1 24
$836.1M
$184.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
DMLP
DMLP
Operating Cash FlowLast quarter
$14.4M
$34.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.12×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
DMLP
DMLP
Q4 25
$34.3M
Q3 25
$14.4M
$34.3M
Q2 25
$30.5M
Q1 25
$23.3M
$33.4M
Q4 24
$-5.4M
$31.5M
Q3 24
$5.2M
$43.7M
Q2 24
$29.4M
Q1 24
$-17.4M
$28.0M
Cash Conversion
BIOX
BIOX
DMLP
DMLP
Q4 25
2.12×
Q3 25
3.07×
Q2 25
2.47×
Q1 25
1.89×
Q4 24
-8.85×
2.21×
Q3 24
1.20×
Q2 24
1.25×
Q1 24
-1.78×
1.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

DMLP
DMLP

Royalties$34.0M81%
Other$7.8M19%

Related Comparisons